PROBLEM TO BE SOLVED: To provide highly purified omega-3 fatty acid formulations having an ideal EPA:DHA ratio for treatment of a broad range of cardiovascular, autoimmune, inflammatory, and central nervous system disorders.SOLUTION: The invention provides pharmaceutical formulations comprising EPA and DHA in a weight to weight ratio from about 3.5:1 to about 6.99:1. It is preferred that the formulations contain, as a unit dosage form, at least 50 mg of DHA and at least 300 mg of EPA and in which the content of EPA and DHA in total amount is greater than 84% of the formulation by weight, and the omega-3 fatty acids in total amount is greater than 90% of the formulation by weight respectively. As for the formulation, it is preferred to be provided in form of capsules, such as a gelatin capsule.【課題】広範な心血管障害、自己免疫障害、炎症性障害、及び中枢神経系障害の治療に理想的なＥＰＡ：ＤＨＡ比を有する高純度のオメガ－３脂肪酸製剤の提供。【解決手段】ＥＰＡ及びＤＨＡを約３．５：１～約６．９９：１の重量対重量比で含む、薬学的製剤。前記製剤は、単位剤形として少なくとも５０ｍｇのＤＨＡ及び少なくとも３００ｍｇのＥＰＡを含み、ＥＰＡとＤＨＡを合計で８４重量％を、オメガ－３脂肪酸の合計で９０重量％をそれぞれ上回る含有量であることが好ましい。前記製剤は、ゼラチンカプセル等のカプセルの形態で提供されることが好ましい。【選択図】図１
